Sarepta Therapeutics Inc. (NASDAQ:SRPT) – Research analysts at Jefferies Group raised their Q3 2016 earnings per share estimates for Sarepta Therapeutics in a note issued to investors on Sunday. Jefferies Group analyst G. Wang now expects that the brokerage will earn ($1.33) per share for the quarter, up from their previous estimate of ($1.38). Jefferies Group has a “Hold” rating and a $58.00 price objective on the stock. Jefferies Group also issued estimates for Sarepta Therapeutics’ Q4 2016 earnings at ($1.16) EPS, FY2016 earnings at ($5.13) EPS and FY2017 earnings at $0.35 EPS.
Several other equities research analysts have also recently weighed in on the company. Cowen and Company restated a “market perform” rating on shares of Sarepta Therapeutics in a report on Monday, August 15th. Janney Montgomery Scott upgraded Sarepta Therapeutics from a “neutral” rating to a “buy” rating and increased their target price for the company from $30.00 to $65.00 in a report on Monday, September 19th. William Blair restated an “outperform” rating and set a $88.00 target price on shares of Sarepta Therapeutics in a report on Sunday. Robert W. Baird restated an “outperform” rating and set a $23.00 target price on shares of Sarepta Therapeutics in a report on Monday, July 18th. Finally, JMP Securities restated an “underperform” rating and set a $10.00 target price on shares of Sarepta Therapeutics in a report on Sunday, July 24th. One analyst has rated the stock with a sell rating, five have issued a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $58.12.
Shares of Sarepta Therapeutics (NASDAQ:SRPT) opened at 62.35 on Wednesday. Sarepta Therapeutics has a one year low of $8.00 and a one year high of $63.73. The company’s 50-day moving average price is $39.01 and its 200 day moving average price is $24.87. The company’s market cap is $2.99 billion.
Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Tuesday, July 19th. The company reported ($1.35) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.19) by $0.16. During the same period last year, the company posted ($0.87) earnings per share.
Several institutional investors have recently added to or reduced their stakes in SRPT. Teacher Retirement System of Texas increased its position in Sarepta Therapeutics by 13.6% in the second quarter. Teacher Retirement System of Texas now owns 6,034 shares of the company’s stock worth $115,000 after buying an additional 724 shares during the period. Advisor Group Inc. purchased a new position in Sarepta Therapeutics during the second quarter worth about $154,000. Quantitative Systematic Strategies LLC purchased a new position in Sarepta Therapeutics during the second quarter worth about $211,000. BNP Paribas Arbitrage SA increased its position in Sarepta Therapeutics by 114.0% in the third quarter. BNP Paribas Arbitrage SA now owns 3,541 shares of the company’s stock worth $217,000 after buying an additional 1,886 shares during the period. Finally, National Planning Corp increased its position in Sarepta Therapeutics by 2.1% in the first quarter. National Planning Corp now owns 13,678 shares of the company’s stock worth $242,000 after buying an additional 275 shares during the period. Hedge funds and other institutional investors own 65.29% of the company’s stock.
In other news, SVP David T. Howton sold 7,000 shares of the firm’s stock in a transaction on Thursday, September 22nd. The stock was sold at an average price of $60.00, for a total value of $420,000.00. Following the transaction, the senior vice president now directly owns 28,453 shares in the company, valued at approximately $1,707,180. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, VP Jayant Aphale sold 35,000 shares of the firm’s stock in a transaction on Monday, September 19th. The stock was sold at an average price of $50.00, for a total value of $1,750,000.00. Following the completion of the transaction, the vice president now owns 21,490 shares in the company, valued at $1,074,500. The disclosure for this sale can be found here. 10.90% of the stock is owned by insiders.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.